Asthma Exacerbation, Bronchiolitis, Croup, Lower Respiratory Disease, Pneumonia, Reactive Airway Disease, Upper Respiratory Disease, Viral Lower Respiratory Tract Infections
Conditions
Brief summary
The purpose of this prospective study is to evaluate the efficacy of the ResAppDx software application in the diagnosis of childhood acute respiratory disease, including pneumonia, bronchiolitis, asthma/reactive airways disease, croup, lower respiratory tract disease (LRTD), viral lower respiratory tract infection (vLRTI), and upper respiratory tract disease (URTD).
Interventions
DEVICERecordings of Infants and Children's Cough Sounds
Smartphone recordings of the cough sounds of infants and children presenting to a participating site with signs or symptoms of respiratory disease.
Sponsors
Massachusetts General Hospital
The Cleveland Clinic
Baylor College of Medicine
Baim Institute for Clinical Research
ResApp Health Limited
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
29 Days to 12 Years
Healthy volunteers
No
Inclusion criteria
* Infant or child aged greater than 29 days up to and including their 12th birthday (infant and children pediatric subgroups as defined in Guidance for Industry and Food and Drug Administration Staff: Premarket Assessment of Pediatric Medical Devices dated March 24, 2014) * Presenting to the study site (an outpatient facility, an urgent care center, an Emergency Department, or inpatient ward within 24 hours of admission) with current signs or symptoms of respiratory disease including cough, wheezing, stridor, chest in-drawing/retractions, difficulty breathing, fast breathing, nasal congestion/rhinorrhea, abnormal lung sounds on exam or cyanosis/hypoxemia. * Onset of symptoms within past 14 days * Outpatient or inpatient within 24 hours of admission * Coughing spontaneously or able to cough voluntarily
Exclusion criteria
* Lack of a signed consent form from parent or legal guardian * Lack of signed assent form for children aged 7 years or older who, in the opinion of the investigator, is able to provide assent based on their age, maturity or psychological state. * Need for mechanical ventilatory support ((including invasive, CPAP, or BiPAP)) or high flow nasal cannula * History of structural airways abnormalities, tracheobronchomalacia, or vocal cord abnormalities (e.g. laryngomalacia, tracheomalacia, or bronchomalacia) * Any medical contraindication to voluntary cough, including the following (only enroll if coughing spontaneously): severe respiratory distress, history of pneumothorax, eye/chest/abdominal surgery in past 3 months, hemoptysis in the past month * Too medically unstable to participate in study per treating clinician * Subject previously enrolled in SMARTCOUGH-C-2 study * Tracheostomy present or tube placed
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Diagnosis of pneumonia | 6 months | Positive percent agreement and negative percent agreement to diagnose and rule out pneumonia as compared with (1) World Health Organization (WHO) Primary Endpoint Pneumonia (PEP) plus clinical pneumonia, (2) WHO PEP or Other Infiltrate plus clinical pneumonia, (3) Clinical pneumonia alone |
| Diagnosis of other childhood respiratory diseases | 6 months | Positive percent agreement and negative percent agreement to diagnose and rule out: lower respiratory tract disease (i.e. respiratory condition occurring below the level of the larynx), viral lower respiratory tract infection, bronchiolitis, asthma/reactive airways disease, upper respiratory tract disease, and croup. |
Countries
United States
Outcome results
None listed